Artinis and NIRx Become One Organisation to Accelerate the Future of Neuroscience Research

Elst, the Netherlands, & Berlin, Germany — 3 June 2026

Artinis Medical Systems and NIRx Medical Technologies, two of the world’s leading developers of functional near-infrared spectroscopy (fNIRS) and electroencephalography (EEG) technology, announced that they are operating as one organisation, Artinis & NIRx. This builds on the acquisitions of both companies by specialist healthcare investor Gilde Healthcare in 2025. The merger unites the two businesses behind a single mission: to help more researchers conduct more neuroscience experiments, create knowledge, and publish their findings.

Where the companies previously operated as complementary brands under shared ownership, they now operate as one business with a joined-up, customer-focused organisation. The business is an R&D powerhouse with a unified strategy, a newly established one-company product team, and one product roadmap.

One portfolio spanning wearables to high-density research systems

The combined organisation brings together Artinis’ wearable fNIRS heritage and NIRx’s high-fidelity research systems, together with TMSi’s EEG solutions (acquired by Artinis in 2024). The individual product brands will continue within the broadest portfolio available in the field, from compact wearable devices for real-world and movement studies to lab-based and high-density systems, including hyperscanning, infant research, and integration of fNIRS, EEG, fMRI, TMS, and eye-tracking.

Both companies were founded over twenty years ago by academics and grew up in the same field. That shared history — and a shared obsession with great products, rigorous science, and outstanding researcher support — is the foundation for the new organisation. The founders and leaders of both companies remain actively involved, leading and advising the business.

Growth, not consolidation cuts

Rather than scaling back, the combined organisation is investing and growing, increasing overall headcount and expanding the capacity available to support its growing global community of academic and applied-research users. Customers will continue to work with the products, teams, and contacts they already know, with continuity of service throughout the transition.

fNIRS is still in its early stages while EEG use is more widespread. Bringing Artinis and NIRx together as one team means we can give researchers a more complete toolkit — from wearable systems in the real world to high-fidelity systems for the lab — and innovate faster with a sizeable joined-up R&D team. — Dr. Matthew Stork, Chief Executive Officer

The combined organisation will continue to operate from its existing locations, including Elst and Oldenzaal (the Netherlands), Berlin (Germany), and Orlando (United States).

What this means for Israeli researchers

For labs already running Artinis, NIRx, or TMSi systems, day-to-day support does not change. The value shows up over the next product cycles: a single roadmap covering wearable fNIRS, high-density fNIRS, and high-density EEG means fewer compatibility gaps for groups combining modalities, and a bigger unified R&D team behind each product line. Multimodal setups — fNIRS with EEG, or either with fMRI, TMS, or eye tracking — are precisely the direction the new organisation is now built around.

NBT continues to represent both Artinis and NIRx in Israel. If you’re planning a new fNIRS or EEG setup, or considering adding a second modality to an existing rig, the merged portfolio is now the right place to start the conversation.

Adapted from the official Artinis & NIRx announcement.